(Q47365348)

English

Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study

scientific article published in November 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

1 reference

based on heuristic

inferred from title

Lars Maegdefessel

4

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

author name string

Anja Kaeberich

1

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Iris Reindl

2

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Uwe Raaz

3

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Alexander Vogt

5

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Torsten Linde

6

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Ulrich Steinseifer

7

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Elisabeth Perzborn

8

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Baerbel Hauroeder

9

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Michael Buerke

10

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Karl Werdan

11

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Axel Schlitt

12

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

publication date

1 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Journal of Thrombosis and Thrombolysis

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

32

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

4

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

417-425

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study.

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

International normalized ratio patient self-management for mechanical valves: is it safe enough?

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Low molecular weight heparin after mechanical heart valve replacement

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Perioperative management of patients receiving oral anticoagulants: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry).

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Fluid mechanics of artificial heart valves.

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Shear stress investigation across mechanical heart valve

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Differential effect of materials for surface hemostasis on red blood cell morphology

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0621-6

21 January 2018

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. Results of an in-vitro study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Problems, interventions and complications in long-term oral anticoagulation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heparin-induced thrombocytopenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11239-011-0621-6

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

release_ao73dzrb3zczrovlaahszkczky

1 reference

https://api.fatcat.wiki/v0/release/ao73dzrb3zczrovlaahszkczky

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21773837

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47365348&oldid=2208565733"